Capricor to Present Deramiocel HOPE-3 Data at WMS 2026
SAN DIEGO, Calif. — September 17, 2026 Capricor Therapeutics announced that 24-month data from the HOPE-3 Phase 3 trial...
Capricor Therapeutics
Advertisement
Capricor Advances Deramiocel as FDA Review Continues
SAN DIEGO, August 13, 2026 Capricor Therapeutics continues to advance Deramiocel (CAP-1002) for Duchenne muscular dystrophy (DMD) as the...
Capricor Reaches Key FDA Milestone in DMD
SAN DIEGO, June 26, 2026 Capricor Therapeutics announced that the U.S. Food and Drug Administration (FDA) has scheduled a...
Capricor Unveils Scalable Exosome Platform for Oligonucleotide Delivery
San Diego, California, November 24, 2025 — Capricor Therapeutics, Inc. announced new data at the AAEV 2025 meeting that...
Advertisement
